annb0t
Top 20
Key Insights
Using the 2 Stage Free Cash Flow to Equity, ResMed fair value estimate is US$137 Current share price of US$179 suggests ResMed is potentially 31% overvalued Analyst price target for RMD is US$249, which is 81% above our fair value estimate
Does the August share price for ResMed Inc. (NYSE:RMD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. We will use the...
>>> Read more: ResMed Inc. (NYSE:RMD) Shares Could Be 31% Above Their Intrinsic Value Estimate
Using the 2 Stage Free Cash Flow to Equity, ResMed fair value estimate is US$137 Current share price of US$179 suggests ResMed is potentially 31% overvalued Analyst price target for RMD is US$249, which is 81% above our fair value estimate
Does the August share price for ResMed Inc. (NYSE:RMD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. We will use the...
>>> Read more: ResMed Inc. (NYSE:RMD) Shares Could Be 31% Above Their Intrinsic Value Estimate
